Merck KGaA taps Selexis cell line tech for immuno-oncology antibodies

By Flora Southey contact

- Last updated on GMT

iStock/kasto80
iStock/kasto80

Related tags: Escherichia coli, Dna, Merck kgaa

A Merck KGaA has signed a licensing agreement for Selexis’ SUREtechnology platform and its suspension-adapted CHO-K1 cell line.

Germany’s Merck KGaA will utilise the technology in its immuno-oncology antibody programme. The terms of the agreement were not disclosed.

According to Swiss-based mammalian cell line developer Selexis, the platform will provide Merck with advantages over traditional approaches, including speed, productivity, stability, and flexibility. 

The company said its SUREtechnology ​platform enables the production of virtually any recombinant protein, including those difficult to express in other systems. 

“Selexis’ SUREtechnology platform facilitates the rapid, stable and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to advance an immune-oncology antibody program,” ​a spokesperson told BioPharma-Reporter.

The technology produces a “high-expressing and stable research cell bank in 14 weeks from transfection, is not associated with gene amplifications, or viral transduction or potential future infections,” ​said the firm.

“It also provides seamless integration of the biologics and vaccine development continuum, spanning discovery to commercialization,” ​the spokesperson told us.

In the past year, Selexis has signed licensing deals for its SUREtechnology ​platform with Sanofi​, ASLAN Pharmaceuticals​, Pieris Pharmaceuticals​, Laboratorios Liomont and Progenics Pharmaceuticals.

Related topics: Bio Developments, Cell lines

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Related suppliers

Follow us

Products

View more

Webinars